top of page

Taking on America’s Crumbling Health Insurance System [STAT Summit 2026 Review #29]

Nov 9
5 min read

Report 29. Taking on America’s Crumbling Health Insurance System

Part I. English Version


1. Event / Date & Time

Event: Taking on America’s Crumbling Health Insurance System

Conference: STAT Summit 2026

Date & Time: October 15, 2026 | 12:20 PM EDT


2. Participants

Speakers

- Chris Deacon, J.D. — Founder and CEO, VerSan Consulting


Moderator

- Bob Herman — Business of Health Care Reporter, STAT


3. Summary

Rising Employer Health Costs: The session examined escalating health benefits costs and their impact on workers, employers and access to care.


Transparency and Accountability: A former New Jersey public-employee plan administrator discussed disputes involving contractor practices and the difficulty of obtaining relevant information.


Purchaser-Led Reform: Employers could use price transparency, benefit-manager oversight and alternative contracting to improve value in health coverage.


4. Main Discussion

Employer-Sponsored Insurance and Cost Pressure

Deacon said approximately 160 million Americans receive health insurance through employers. The conversation highlighted double-digit increases in employer benefit costs and the consequences for wages and business decisions. She argued that companies purchasing coverage should more actively scrutinize what they receive for their spending.

Deacon drew on her management of a New Jersey public-employee health plan covering approximately 820,000 people. She recalled seeing claim-level discrepancies that, in her view, indicated excessive payments under arrangements with contracted administrators. In one example, she compared a plan-paid amount of approximately $2.1 million with underlying billing information and referred to more than $18 million paid above billed amounts across 50 claims. These numbers were her account of the dispute, not an independent audit reproduced in the session. Her narrative illustrated how difficult it can be for a plan sponsor to know what it is actually paying when data and contractual rules are controlled by intermediaries.

Deacon placed the issue in the context of employer-sponsored coverage used by approximately 160 million Americans. She described managing health benefits for roughly 820,000 New Jersey public employees and dependents, where she encountered billing data that appeared inconsistent with the services and amounts represented to the plan. Her account suggested that purchasers can pay substantial sums without access to the underlying information necessary to determine whether charges are reasonable. Costs then flow into public budgets, employer spending and employees’ compensation. These claims were presented from her professional and whistleblower experience; they should not be read as a statistical estimate of overpayment across all employer plans.


New Jersey Plan and Whistleblower Experience

Drawing on management of New Jersey’s public-employee health plan covering around 820,000 people, Deacon described concerns about insurer and contractor arrangements that led to a whistleblower dispute and settlement. She discussed pressure and practical obstacles involved in challenging established contracting systems. Her description reflected her account of the events.

The story included litigation and a $100 million settlement associated with allegations involving a health-plan contractor. Deacon said she was distressed by the handling of her whistleblower role and described tensions around document access and the settlement process. The report does not independently decide the legal merits of those allegations or attribute findings beyond what participants stated. The policy relevance of the account lies in the asymmetry of information between employers or public plans that pay for benefits and the administrators, networks and pharmacy benefit managers that organize payment. Where actual contracted prices are difficult to verify, headline discounts can obscure rather than clarify whether a deal is advantageous.

The whistleblower case was described through a concrete review of claims data, including a sample in which amounts paid by the plan exceeded amounts apparently billed by providers. Deacon referred to approximately $18 million in excess payments across 50 claims and a subsequent $100 million settlement involving a health-benefit contractor. She also described a dispute over her status as a whistleblower and the handling of documents. The session offered a first-person account of a legal and administrative process; readers should distinguish the fact of a reported settlement from disputed claims about motives or individual actions. The broader institutional question is what independent audit rights employers retain under complex vendor contracts.


Pharmacy Benefit Managers and Contracting

The discussion addressed greater employer interest in alternatives to traditional pharmacy benefit manager (PBM) models. Deacon suggested reviewing contracts, incentives and pharmacy spending rather than automatically renewing established arrangements. A key issue was whether intermediaries’ financial interests align with employers and patients.

The scale of employer-sponsored coverage made the issue broader than a single procurement dispute. Deacon estimated that approximately 160 million Americans obtain health insurance through employment; rising benefit costs thus affect workers’ disposable income and employers’ budgets. She discussed network discounts whose percentages looked attractive without revealing whether the starting price was inflated. Later in the discussion, she cited premium growth of about 25% in the preceding year and an additional expected 15% in 2027; these were the figures and expectations presented at the event. The argument was that benefit purchasers require access to usable net-price information and the capacity to compare arrangements, not just summary documents prepared by intermediaries.

Pharmacy benefit managers, third-party administrators and insurance vendors form a chain of contractual relationships that can obscure the amount paid to pharmacies or clinicians, the fees retained by intermediaries and the ultimate price charged to a plan. The panel questioned whether purchasers receive timely and usable data rather than selectively formatted summary reports. Deacon argued that transparency must be actionable: the ability to inspect contract terms, trace individual claims and challenge discrepancies. Disclosure alone is insufficient if the purchaser cannot reconcile amounts or exercise remedies. This point is directly relevant to organizations procuring costly specialty therapies as well as conventional employee benefits.


Price Data and Practical Transparency

Deacon urged employers to compare negotiated provider rates using publicly available price-transparency information. She also described delays in public-records requests, arguing that disclosure requirements alone are insufficient when data remain difficult to obtain or use.

Participants acknowledged that price transparency alone cannot turn all of healthcare into a consumer shopping market. Emergency situations, complex treatment pathways and differences in clinical quality limit when individuals can compare options in advance. Deacon nevertheless argued that the purchasers of coverage should have the information required to assess administrators’ performance and negotiate responsibly. For biotech companies and care providers, opaque reimbursement can shape adoption of diagnostics and therapies irrespective of their clinical merit. The session’s broader implication was the need for better disclosure, purchaser expertise and accountability mechanisms, rather than assuming that any single data tool or policy change will repair the entire insurance market.

The discussion closed on obstacles to obtaining records and the difficulty of sustaining institutional accountability over long vendor relationships. Procurement decisions may rely heavily on established contractors, making independent challenge politically and operationally costly. Deacon presented herself as advocating for employers and public purchasers to exercise greater control over health-benefit spending, while the moderator emphasized the implications for wages and business operations. The session did not offer a comprehensive national reform design. It showed, through one case, how better contractual audit provisions, access to unfiltered claims data and independent review could become practical steps toward cost governance.


5. Insights

Purchasing and Access: Insurance design, contracting and transparency can substantially shape whether healthcare innovation is affordable to patients.


Implications for South Korea: Korea could use the discussion as a comparative case when assessing transparency and purchaser incentives in healthcare financing.


Data-Enabled Oversight: More usable pricing and claims information may support accountability across insurers, employers and providers.



Comments


© 2026 KHIDI USA ALL RIGHT RESERVED

bottom of page